leadf
logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics - Results of EGM

RNS Number : 9399T
Silence Therapeutics PLC
23 July 2020
 

 

Results of General Meeting

 

London, 23rd July 2020

 

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that at its  General Meeting held today, Thursday, 23rd July 2020, all resolutions set out in the notice of meeting were duly passed on a poll.

 

The votes were as follows:

 

Resolution

Votes for

%

Votes against

%

Votes total

% of ISC voted

Votes withheld

1 - Restatement of long term incentive plans (ordinary resolution)

38,168,851

98.0

772,001

2.0

38,940,852

47.0

4,276,757

2 - Approval of US Employee Sub-Plan (ordinary resolution)

38,185,627

98.1

755,225

1.9

38,940,852

47.0

4,276,757

3 - Approval of new articles of association (special resolution)

38,940,642

100

210

0

38,940,852

47.0

4,276,757

 

The number of the Company's ordinary shares in issue as at the date of the meeting was 82,826,259 ordinary shares of 5p each.

 

A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.

 

Enquiries:

 

Silence Therapeutics plc

Iain Ross, Executive Chairman

Dr Rob Quinn, Chief Financial Officer

 

 

Tel:  +44 (0)20 3457 6900

  Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

  Tel:  +44 (0) 20 7597 5970

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 

 Tel: +1 (443) 213-0505

 

Notes to Editors

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ROMFLFEEDTIVFII

Quick facts: Silence Therapeutics PLC

Price: 435

Market: AIM
Market Cap: £360.29 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE 100 retreats as UK employment tumbles

Headlines from the Proactive UK newsroom. The FTSE100 was on the back foot as the new job numbers highlighted how business is suffering due to the pandemic. The blue chip-index shed 60 to 6,232. People on UK payrolls fell by 649,000 between March and June, according to the government....

on 16/7/20